CJC-1295 With DAC (5mg)

GHRH Receptor Activation and cAMP/PKA Signaling

GHRH-R Activation — CJC-1295 DAC exerts its primary biological effects through high-affinity binding to the growth hormone-releasing hormone receptor (GHRH-R), a class B1 G-protein coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary gland. Upon ligand binding, GHRH-R couples to the stimulatory G-protein alpha subunit (Gαs), activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB induces expression of the pituitary-specific transcription factor Pit-1, which in turn drives transcription of the growth hormone gene (GH1), leading to both synthesis and secretion of GH from somatotroph cells.

Sustained GH/IGF-1 Axis Stimulation via Albumin Conjugation

DAC-Albumin Reservoir — The DAC modification fundamentally alters the pharmacokinetic and pharmacodynamic profile of CJC-1295 compared to both native GHRH and the non-DAC analog. Upon subcutaneous injection, the maleimide group on Lys³⁰ rapidly conjugates to albumin Cys-34, creating a circulating peptide-albumin reservoir that slowly dissociates and activates pituitary GHRH-R over days rather than minutes. Single subcutaneous injections produced dose-dependent GH elevations of 2- to 10-fold persisting for six or more days, and IGF-1 increases of 1.5- to 3-fold lasting 9-11 days. This pharmacokinetic profile produces a shift from the pulsatile GH release pattern characteristic of native GHRH to a more sustained, tonic GH elevation while maintaining the physiological pulsatile pattern and intact somatostatin-mediated negative feedback mechanisms.

Somatotroph Trophic Effects and Proliferation

Pituitary Cell Growth — Beyond acute GH secretagogue activity, CJC-1295 demonstrates trophic effects on pituitary somatotroph cells. In GHRH knockout (GHRHKO) mice lacking endogenous GHRH signaling, daily administration of CJC-1295 for five weeks produced significant somatotroph cell proliferation confirmed by immunohistochemistry. Treatment increased total pituitary RNA content and GH mRNA expression, indicating both cellular proliferation and enhanced biosynthetic capacity. Daily dosing normalized body weight, body length, and femur/tibia dimensions in these growth-deficient animals. However, research by Ben-Shlomo et al. (2020) demonstrated that chronic cAMP elevation from sustained GHRH-R stimulation can induce DNA damage markers (phosphorylated gamma-H2AX) in somatotroph cells in a dose-dependent manner, suggesting that prolonged overstimulation may carry proliferative risks.